Response of Human Intestinal Lamina Propria T Lymphocytes to Interleukin 12: Additive Effects of Interleukin 15 and 7
Overview
Authors
Affiliations
Background/aim: Interleukin (IL) 12 is involved in the mucosal response during intestinal inflammation but its role is not fully understood. The response of human lamina propria T lymphocytes (T-LPL) to IL-12 in terms of interferon gamma (IFN-gamma) release and proliferation was investigated, exploring whether IL-15 and IL-7 cooperate with IL-12. The role of accessory molecules (CD2 and CD28) was also investigated.
Methods: Unstimulated and phytohaemagglutinin preactivated T-LPL cultures were incubated with or without the initial addition of cytokines, anti-CD2 or anti-CD28 antibodies. IFN-gamma mRNA was detected by reverse transcriptase polymerase chain reaction, and protein secretion was measured by enzyme linked immunosorbent assay (ELISA).
Results: IFN-gamma mRNA was induced in T-LPLs by IL-12 and IL-15 but not IL-7, whereas IFN-gamma was measured only in IL-12 stimulated T-LPL cultures. IL-12 induced IFN-gamma release was not abrogated by neutralising anti-IL-2 antibody or by cyclosporin A. IL-12 synergised with either anti-CD2 or anti-CD28 antibodies in inducing IFN-gamma synthesis. In preactivated T-LPLs, IL-7 enhanced IFN-gamma release induced by both IL-12 and anti-CD2, whereas IL-15 potentiated only IL-12 induced IFN-gamma synthesis. IL-12 did not induce proliferation of either unstimulated or preactivated T-LPLs and it did not enhance the CD2/CD28 stimulated T-LPL proliferative response. No transcript for IL-12 receptor beta1 subunit was detected in freshly isolated and activated T-LPLs whereas the beta2 subunit mRNA was consistently found in T-LPL samples.
Conclusions: IL-12 induces human T-LPLs to produce and release IFN-gamma, and IL-15 and IL-7 cooperate with IL-12 in expanding the IFN-gamma mucosal response.
Intestinal Immune Imbalance is an Alarm in the Development of IBD.
Hu C, Liao S, Lv L, Li C, Mei Z Mediators Inflamm. 2023; 2023:1073984.
PMID: 37554552 PMC: 10406561. DOI: 10.1155/2023/1073984.
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
Verstockt B, Salas A, Sands B, Abraham C, Leibovitzh H, Neurath M Nat Rev Gastroenterol Hepatol. 2023; 20(7):433-446.
PMID: 37069321 PMC: 10958371. DOI: 10.1038/s41575-023-00768-1.
Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach.
Genaro L, Gomes L, Franceschini A, Ceccato H, de Jesus R, Lima A Am J Transl Res. 2022; 13(12):13916-13930.
PMID: 35035733 PMC: 8748125.
Metalloproteinases in Inflammatory Bowel Diseases.
Maronek M, Marafini I, Gardlik R, Link R, Troncone E, Monteleone G J Inflamm Res. 2021; 14:1029-1041.
PMID: 33790618 PMC: 8001665. DOI: 10.2147/JIR.S288280.
Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G Clin Exp Gastroenterol. 2020; 13:131-139.
PMID: 32440190 PMC: 7211304. DOI: 10.2147/CEG.S208020.